Cargando…

Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study

The heme catabolite bilirubin has anti-inflammatory, anti-oxidative and anti-mutagenic effects and its relation to colorectal cancer (CRC) risk is currently under evaluation. Although the main metabolic steps of bilirubin metabolism, including the formation of stercobilin and urobilin, take place in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zöhrer, Patrick A., Hana, Claudia A., Seyed Khoei, Nazlisadat, Mölzer, Christine, Hörmann-Wallner, Marlies, Tosevska, Anela, Doberer, Daniel, Marculescu, Rodrig, Bulmer, Andrew C., Herbold, Craig W., Berry, David, Wagner, Karl-Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481893/
https://www.ncbi.nlm.nih.gov/pubmed/34604105
http://dx.doi.org/10.3389/fcimb.2021.701109
_version_ 1784576783948972032
author Zöhrer, Patrick A.
Hana, Claudia A.
Seyed Khoei, Nazlisadat
Mölzer, Christine
Hörmann-Wallner, Marlies
Tosevska, Anela
Doberer, Daniel
Marculescu, Rodrig
Bulmer, Andrew C.
Herbold, Craig W.
Berry, David
Wagner, Karl-Heinz
author_facet Zöhrer, Patrick A.
Hana, Claudia A.
Seyed Khoei, Nazlisadat
Mölzer, Christine
Hörmann-Wallner, Marlies
Tosevska, Anela
Doberer, Daniel
Marculescu, Rodrig
Bulmer, Andrew C.
Herbold, Craig W.
Berry, David
Wagner, Karl-Heinz
author_sort Zöhrer, Patrick A.
collection PubMed
description The heme catabolite bilirubin has anti-inflammatory, anti-oxidative and anti-mutagenic effects and its relation to colorectal cancer (CRC) risk is currently under evaluation. Although the main metabolic steps of bilirubin metabolism, including the formation of stercobilin and urobilin, take place in the human gastrointestinal tract, potential interactions with the human gut microbiota are unexplored. This study investigated, whether gut microbiota composition is altered in Gilbert’s Syndrome (GS), a mild form of chronically elevated serum unconjugated bilirubin (UCB) compared to matched controls. Potential differences in the incidence of CRC-associated bacterial species in GS were also assessed. To this end, a secondary investigation of the BILIHEALTH study was performed, assessing 45 adults with elevated UCB levels (GS) against 45 age- and sex-matched controls (C). Fecal microbiota analysis was performed using 16S rRNA gene sequencing. No association between mildly increased UCB and the composition of the gut microbiota in this healthy cohort was found. The alpha and beta diversity did not differ between C and GS and both groups showed a typical representation of the known dominant phyla. Furthermore, no difference in abundance of Firmicutes and Proteobacteria, which have been associated with the mucosa of CRC patients were observed between the groups. A sequence related to the Christensenella minuta strain YIT 12065 was identified with a weak association value of 0.521 as an indicator species in the GS group. This strain has been previously associated with a lower body mass index, which is typical for the GS phenotype. Overall, sex was the only driver for an identifiable difference in the study groups, as demonstrated by a greater bacterial diversity in women. After adjusting for confounding factors and multiple testing, we can conclude that the GS phenotype does not affect the composition of the human gut microbiota in this generally healthy study group.
format Online
Article
Text
id pubmed-8481893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84818932021-10-01 Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study Zöhrer, Patrick A. Hana, Claudia A. Seyed Khoei, Nazlisadat Mölzer, Christine Hörmann-Wallner, Marlies Tosevska, Anela Doberer, Daniel Marculescu, Rodrig Bulmer, Andrew C. Herbold, Craig W. Berry, David Wagner, Karl-Heinz Front Cell Infect Microbiol Cellular and Infection Microbiology The heme catabolite bilirubin has anti-inflammatory, anti-oxidative and anti-mutagenic effects and its relation to colorectal cancer (CRC) risk is currently under evaluation. Although the main metabolic steps of bilirubin metabolism, including the formation of stercobilin and urobilin, take place in the human gastrointestinal tract, potential interactions with the human gut microbiota are unexplored. This study investigated, whether gut microbiota composition is altered in Gilbert’s Syndrome (GS), a mild form of chronically elevated serum unconjugated bilirubin (UCB) compared to matched controls. Potential differences in the incidence of CRC-associated bacterial species in GS were also assessed. To this end, a secondary investigation of the BILIHEALTH study was performed, assessing 45 adults with elevated UCB levels (GS) against 45 age- and sex-matched controls (C). Fecal microbiota analysis was performed using 16S rRNA gene sequencing. No association between mildly increased UCB and the composition of the gut microbiota in this healthy cohort was found. The alpha and beta diversity did not differ between C and GS and both groups showed a typical representation of the known dominant phyla. Furthermore, no difference in abundance of Firmicutes and Proteobacteria, which have been associated with the mucosa of CRC patients were observed between the groups. A sequence related to the Christensenella minuta strain YIT 12065 was identified with a weak association value of 0.521 as an indicator species in the GS group. This strain has been previously associated with a lower body mass index, which is typical for the GS phenotype. Overall, sex was the only driver for an identifiable difference in the study groups, as demonstrated by a greater bacterial diversity in women. After adjusting for confounding factors and multiple testing, we can conclude that the GS phenotype does not affect the composition of the human gut microbiota in this generally healthy study group. Frontiers Media S.A. 2021-09-16 /pmc/articles/PMC8481893/ /pubmed/34604105 http://dx.doi.org/10.3389/fcimb.2021.701109 Text en Copyright © 2021 Zöhrer, Hana, Seyed Khoei, Mölzer, Hörmann-Wallner, Tosevska, Doberer, Marculescu, Bulmer, Herbold, Berry and Wagner https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Zöhrer, Patrick A.
Hana, Claudia A.
Seyed Khoei, Nazlisadat
Mölzer, Christine
Hörmann-Wallner, Marlies
Tosevska, Anela
Doberer, Daniel
Marculescu, Rodrig
Bulmer, Andrew C.
Herbold, Craig W.
Berry, David
Wagner, Karl-Heinz
Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study
title Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study
title_full Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study
title_fullStr Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study
title_full_unstemmed Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study
title_short Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study
title_sort gilbert’s syndrome and the gut microbiota – insights from the case-control bilihealth study
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481893/
https://www.ncbi.nlm.nih.gov/pubmed/34604105
http://dx.doi.org/10.3389/fcimb.2021.701109
work_keys_str_mv AT zohrerpatricka gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT hanaclaudiaa gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT seyedkhoeinazlisadat gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT molzerchristine gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT hormannwallnermarlies gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT tosevskaanela gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT dobererdaniel gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT marculescurodrig gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT bulmerandrewc gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT herboldcraigw gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT berrydavid gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy
AT wagnerkarlheinz gilbertssyndromeandthegutmicrobiotainsightsfromthecasecontrolbilihealthstudy